170 related articles for article (PubMed ID: 15990113)
1. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis.
Nagano I; Ilieva H; Shiote M; Murakami T; Yokoyama M; Shoji M; Abe K
J Neurol Sci; 2005 Aug; 235(1-2):61-8. PubMed ID: 15990113
[TBL] [Abstract][Full Text] [Related]
2. Prevention of spinal motor neuron death by insulin-like growth factor-1 associating with the signal transduction systems in SODG93A transgenic mice.
Narai H; Nagano I; Ilieva H; Shiote M; Nagata T; Hayashi T; Shoji M; Abe K
J Neurosci Res; 2005 Nov; 82(4):452-7. PubMed ID: 16235250
[TBL] [Abstract][Full Text] [Related]
3. [Development of motor neuron restorative therapy in amyotrophic lateral sclerosis using hepatocyte growth factor].
Aoki M; Warita H; Suzuki N; Itoyama Y
Rinsho Shinkeigaku; 2009 Nov; 49(11):814-7. PubMed ID: 20030218
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis.
Ohta Y; Kamiya T; Nagai M; Nagata T; Morimoto N; Miyazaki K; Murakami T; Kurata T; Takehisa Y; Ikeda Y; Asoh S; Ohta S; Abe K
J Neurosci Res; 2008 Oct; 86(13):3028-37. PubMed ID: 18543336
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model.
Ishigaki A; Aoki M; Nagai M; Warita H; Kato S; Kato M; Nakamura T; Funakoshi H; Itoyama Y
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1037-44. PubMed ID: 17984685
[TBL] [Abstract][Full Text] [Related]
6. VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death.
Li B; Xu W; Luo C; Gozal D; Liu R
Brain Res Mol Brain Res; 2003 Mar; 111(1-2):155-64. PubMed ID: 12654515
[TBL] [Abstract][Full Text] [Related]
7. Sertoli cells improve survival of motor neurons in SOD1 transgenic mice, a model of amyotrophic lateral sclerosis.
Hemendinger R; Wang J; Malik S; Persinski R; Copeland J; Emerich D; Gores P; Halberstadt C; Rosenfeld J
Exp Neurol; 2005 Dec; 196(2):235-43. PubMed ID: 16242126
[TBL] [Abstract][Full Text] [Related]
8. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS.
Messi ML; Clark HM; Prevette DM; Oppenheim RW; Delbono O
Exp Neurol; 2007 Sep; 207(1):52-63. PubMed ID: 17597610
[TBL] [Abstract][Full Text] [Related]
9. Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity.
Saenger S; Holtmann B; Nilges MR; Schroeder S; Hoeflich A; Kletzl H; Spooren W; Ostrowitzki S; Hanania T; Sendtner M; Metzger F
Amyotroph Lateral Scler; 2012 Sep; 13(5):418-29. PubMed ID: 22871074
[TBL] [Abstract][Full Text] [Related]
10. [Amyotrophic lateral sclerosis with the SOD1 mutations].
Aoki M; Warita H; Itoyama Y
Rinsho Shinkeigaku; 2008 Nov; 48(11):966-9. PubMed ID: 19198133
[TBL] [Abstract][Full Text] [Related]
11. IGF-1:tetanus toxin fragment C fusion protein improves delivery of IGF-1 to spinal cord but fails to prolong survival of ALS mice.
Chian RJ; Li J; Ay I; Celia SA; Kashi BB; Tamrazian E; Matthews JC; Bronson RT; Rossomando A; Pepinsky RB; Fishman PS; Brown RH; Francis JW
Brain Res; 2009 Sep; 1287():1-19. PubMed ID: 19563785
[TBL] [Abstract][Full Text] [Related]
12. Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice.
Zhang X; Chen S; Li L; Wang Q; Le W
Neuropharmacology; 2008 Jun; 54(7):1112-9. PubMed ID: 18436268
[TBL] [Abstract][Full Text] [Related]
13. Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis.
Zhang C; Zhou C; Teng JJ; Zhao RL; Song YQ; Zhang C
Cytotherapy; 2009; 11(3):299-306. PubMed ID: 19333801
[TBL] [Abstract][Full Text] [Related]
14. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo.
Chiba T; Hashimoto Y; Tajima H; Yamada M; Kato R; Niikura T; Terashita K; Schulman H; Aiso S; Kita Y; Matsuoka M; Nishimoto I
J Neurosci Res; 2004 Nov; 78(4):542-52. PubMed ID: 15478191
[TBL] [Abstract][Full Text] [Related]
16. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.
Kaspar BK; Lladó J; Sherkat N; Rothstein JD; Gage FH
Science; 2003 Aug; 301(5634):839-42. PubMed ID: 12907804
[TBL] [Abstract][Full Text] [Related]
17. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model.
Wang R; Zhang D
Eur J Neurosci; 2005 Nov; 22(9):2376-80. PubMed ID: 16262676
[TBL] [Abstract][Full Text] [Related]
18. DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis.
Feng X; Peng Y; Liu M; Cui L
Neuropharmacology; 2012 Feb; 62(2):1004-10. PubMed ID: 22056419
[TBL] [Abstract][Full Text] [Related]
19. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice.
Crow JP; Calingasan NY; Chen J; Hill JL; Beal MF
Ann Neurol; 2005 Aug; 58(2):258-65. PubMed ID: 16049935
[TBL] [Abstract][Full Text] [Related]
20. Absence of p53: no effect in a transgenic mouse model of familial amyotrophic lateral sclerosis.
Kuntz C; Kinoshita Y; Beal MF; Donehower LA; Morrison RS
Exp Neurol; 2000 Sep; 165(1):184-90. PubMed ID: 10964497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
